- Home
- STOK
as 04-18-2025 1:43pm EST
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 379.6M | IPO Year: | 2019 |
| Target Price: | $26.00 | AVG Volume (30 days): | 987.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.35 - $17.58 | Next Earning Date: | 05-05-2025 |
| Revenue: | $36,555,000 | Revenue Growth: | 316.34% |
| Revenue Growth (this year): | 27.8% | Revenue Growth (next year): | 9.53% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Mar 18 '25 | Sell | $8.47 | 7,217 | $61,238.19 | 63,962 | |
| Kaye Edward M. MD | STOK | Director | Mar 18 '25 | Sell | $8.47 | 19,289 | $163,672.83 | 148,253 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Mar 18 '25 | Sell | $8.47 | 4,211 | $35,731.37 | 33,510 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Business Wire
17 days ago
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
a month ago
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Investopedia
a month ago
Stoke Therapeutics Stock Slips as CEO Steps Down
Zacks
a month ago
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
BioPharma Dive
a month ago
Stoke CEO exits; Medicare drug price talks advance
MT Newswires
a month ago
Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named
Business Wire
a month ago
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Business Wire
a month ago
Stoke Therapeutics Announces CEO Transition
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.